Outlook Therapeutics, Inc. (OTLK) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 1236331,
    "name": "Outlook Therapeutics, Inc.",
    "stock_name": "Outlook Therapeutics, Inc.",
    "full_name": "Outlook Therapeutics, Inc.",
    "name_url": "stocks-analysis/outlook-therapeutics-inc",
    "exchange": 210,
    "exchangecode": "NAS",
    "country_id": 2,
    "currency": "USD",
    "cmp": "2.06",
    "chg": 0.23,
    "chgp": "12.57%",
    "dir": 1,
    "prev_price": "1.83",
    "mcapval": "42.01",
    "mcap": "Micro Cap",
    "scripcode": "",
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 2305,
    "indexname": "S&P 500",
    "isin": "US69012T2069",
    "curr_date": "Dec 04",
    "curr_time": "",
    "bse_nse_vol": "739.99 k",
    "exc_status": "Active",
    "traded_date": "Dec 04, 2025",
    "traded_date_str": "2025 12 04",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/outlook-therapeutics-inc-1236331-210&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Outlook Therapeutics Forms Death Cross, Signaling Bearish Trend Ahead",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/outlook-therapeutics-forms-death-cross-signaling-bearish-trend-ahead-3595236",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/OutlookTherapeu_dealthcross_3595236.png",
        "date": "2025-10-06 15:21:52",
        "description": "Outlook Therapeutics, Inc. has recently encountered a technical event known as a Death Cross, indicating potential bearish market sentiment. The stock's daily moving averages and broader indicators reflect a negative trend, with a significant decline of 79.81% over the past year, underperforming the S&P 500."
      },
      {
        "title": "Is Outlook Therapeutics, Inc. technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-outlook-therapeutics-inc-technically-bullish-or-bearish-3547351",
        "imagepath": "",
        "date": "2025-09-20 19:53:25",
        "description": "As of 9 September 2025, the technical trend for Outlook Therapeutics, Inc. has changed from mildly bullish to sideways. The current technical stance is neutral, with mixed signals across various indicators. The weekly MACD is bearish, while the monthly MACD shows a mildly bullish trend. The RSI indicates no signal on the weekly timeframe but is bullish on the monthly. Moving averages are mildly bullish on the daily, but Bollinger Bands are bearish on the weekly and mildly bearish on the monthly. KST is mildly bearish weekly and bearish monthly, and there are no trends indicated by Dow Theory or OBV.\n\nIn terms of performance, the stock has significantly underperformed compared to the S&P 500 across all periods, with a 1-year return of -83.31% versus the S&P 500's 17.14%...."
      },
      {
        "title": "Is Outlook Therapeutics, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-outlook-therapeutics-inc-overvalued-or-undervalued-3543741",
        "imagepath": "",
        "date": "2025-09-20 18:27:31",
        "description": "As of 14 August 2025, the valuation grade for Outlook Therapeutics, Inc. has moved from does not qualify to risky, indicating a significant deterioration in its perceived value. The company appears to be overvalued given its negative valuation ratios, including a Price to Book Value of -2.51 and an EV to EBITDA of -1.40. Additionally, the EV to Capital Employed ratio stands at -15.46, further highlighting the company's financial challenges.\n\nIn comparison to its peers, Outlook Therapeutics, Inc. has a less favorable position, with ADC Therapeutics SA showing a more negative P/E of -2.4050 and Kinnate Biopharma, Inc. being rated fair with an EV to EBITDA of 0.2381. The company's stock performance has been notably poor, with a 1-year return of -83.31% compared to the S&P 500's positive return of 17.14%, reinforcing the notion that the stock is currently overvalued...."
      }
    ],
    "total": 8,
    "sid": "1236331",
    "stock_news_url": "https://www.marketsmojo.com/news/outlook-therapeutics-inc-1236331"
  },
  "announcements": "",
  "corporate_actions": {
    "msg": "No corporate action Found"
  }
}

News and Views

Outlook Therapeutics Forms Death Cross, Signaling Bearish Trend Ahead

2025-10-06 15:21:52

Outlook Therapeutics, Inc. has recently encountered a technical event known as a Death Cross, indicating potential bearish market sentiment. The stock's daily moving averages and broader indicators reflect a negative trend, with a significant decline of 79.81% over the past year, underperforming the S&P 500.

Is Outlook Therapeutics, Inc. technically bullish or bearish?

2025-09-20 19:53:25

As of 9 September 2025, the technical trend for Outlook Therapeutics, Inc. has changed from mildly bullish to sideways. The current technical stance is neutral, with mixed signals across various indicators. The weekly MACD is bearish, while the monthly MACD shows a mildly bullish trend. The RSI indicates no signal on the weekly timeframe but is bullish on the monthly. Moving averages are mildly bullish on the daily, but Bollinger Bands are bearish on the weekly and mildly bearish on the monthly. KST is mildly bearish weekly and bearish monthly, and there are no trends indicated by Dow Theory or OBV. In terms of performance, the stock has significantly underperformed compared to the S&P 500 across all periods, with a 1-year return of -83.31% versus the S&P 500's 17.14%....

Is Outlook Therapeutics, Inc. overvalued or undervalued?

2025-09-20 18:27:31

As of 14 August 2025, the valuation grade for Outlook Therapeutics, Inc. has moved from does not qualify to risky, indicating a significant deterioration in its perceived value. The company appears to be overvalued given its negative valuation ratios, including a Price to Book Value of -2.51 and an EV to EBITDA of -1.40. Additionally, the EV to Capital Employed ratio stands at -15.46, further highlighting the company's financial challenges. In comparison to its peers, Outlook Therapeutics, Inc. has a less favorable position, with ADC Therapeutics SA showing a more negative P/E of -2.4050 and Kinnate Biopharma, Inc. being rated fair with an EV to EBITDA of 0.2381. The company's stock performance has been notably poor, with a 1-year return of -83.31% compared to the S&P 500's positive return of 17.14%, reinforcing the notion that the stock is currently overvalued....

View All News